Jan 14, 2026 18:25
VKTX - Viking Therapeutics, Inc
| Day | 1m | 10m | 60m | PreMarket | Market | AfterHours | Gap |
|---|---|---|---|---|---|---|---|
| 33.76 0.56 (1.66%) | -0.02 (-0.04%) | -0.09 (-0.26%) | -0.1 (-0.29%) | 0.29 (0.86%) | 0.29 (0.85%) | -0.68 (-1.99%) | -0.1 (-0.29%) |
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Category:
PHARMACEUTICAL PREPARATIONS
Market Period:
Closed
Earnings & Ratios
- Basic EPS:
- -0.58
- Diluted EPS:
- -0.58
- Basic P/E:
- -59.1724
- Diluted P/E:
- -59.1724
- RSI(14) 1m:
- 57.42
- VWAP:
- 34.34
- RVol:
Events
| Period | Kind | Movement | Occurred At |
|---|
Related News
Jan 05, 2026 21:03
Dec 16, 2025 18:15
Dec 13, 2025 15:15
Dec 13, 2025 09:10
Dec 11, 2025 12:15
Dec 10, 2025 17:42
Nov 27, 2025 13:15
Nov 25, 2025 21:05
Nov 22, 2025 14:20